Allyx Therapeutics aims to deliver a novel approach to preserve and protect synapses for people living with neurodegenerative diseases. Its lead compound, ALX-001, is a first-in-class oral therapy with a unique mechanism of action at mGluR5. Clinical programs are currently underway in Alzheimer’s disease (Phase 1b). The company was founded in 2019 by a group of Yale scientists, seasoned biopharma industry executives, and venture capitalists.
Allyx is a Series A stage company and has extensively leveraged both public and private non-dilutive funding sources including funds from the National Institutes of Health (NIH).